Amneal Launches Amicar Rival With CGT Exclusivity

Also Introduces US Rivals To Revatio And Carafate

After receiving FDA approval for its generic aminocaproic acid with 180 days of exclusivity under the agency’s Competitive Generic Therapy pathway, Amneal has launched the rival to Amicar. At the same time, it has also begun selling a generic version of Revatio and has also claimed the first generic rival to Carafate.

Exclusive_Stamp
Amneal will enjoy 180 days of exclusivity for its Amicar rival • Source: Shutterstock

Amneal has launched generic aminocaproic acid 500mg tablets with 180 days of exclusivity in the US, after receiving US Food and Drug Administration approval for the rival to Amicar which had previously been granted a Competitive Generic Therapy designation by the agency.

Guidance on the CGT pathway was published by the FDA earlier this year “to encourage generic entry for drugs that...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Products

More from Generics Bulletin